Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Hims & Hers Health beat revenue estimates in Q3 2025 with $599M, driven by subscriber growth and higher spending, despite missing earnings due to rising costs.
Hims & Hers Health reported $599 million in third-quarter 2025 revenue, beating estimates and marking a 49% year-over-year increase, driven by a 21% rise in subscribers to 2.47 million and higher per-user spending.
Despite missing earnings per share expectations due to increased costs from its shift to compounded drugs and supply chain investments, the company saw strong adjusted EBITDA growth.
It announced renewed talks with Novo Nordisk to potentially distribute Wegovy and an oral semaglutide version, reversing a June partnership termination.
The company expects $725 million in GLP-1 revenue by 2026 and reaffirmed its 2030 revenue target of $6.5 billion, citing investments in diagnostics, women’s health, and global expansion.
Shares rose after hours on the news.
Hims & Hers Health superó las estimaciones de ingresos en el tercer trimestre de 2025 con $ 599M, impulsadas por el crecimiento de los suscriptores y el aumento del gasto, a pesar de las ganancias perdidas debido al aumento de los costos.